WO2002072051A2 - Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations - Google Patents

Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations Download PDF

Info

Publication number
WO2002072051A2
WO2002072051A2 PCT/EP2002/002027 EP0202027W WO02072051A2 WO 2002072051 A2 WO2002072051 A2 WO 2002072051A2 EP 0202027 W EP0202027 W EP 0202027W WO 02072051 A2 WO02072051 A2 WO 02072051A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
phospholipid complexes
pharmaceutical
extracted
cosmetic compositions
Prior art date
Application number
PCT/EP2002/002027
Other languages
French (fr)
Other versions
WO2002072051A3 (en
Inventor
Francesco Di Pierro
Original Assignee
Indena S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2439685A priority Critical patent/CA2439685C/en
Priority to KR1020037010928A priority patent/KR100894581B1/en
Priority to AU2002237310A priority patent/AU2002237310B2/en
Priority to HU0303375A priority patent/HU230038B1/en
Priority to US10/469,300 priority patent/US7374748B2/en
Priority to SK1088-2003A priority patent/SK285876B6/en
Priority to EP02703604A priority patent/EP1363588B1/en
Application filed by Indena S.P.A. filed Critical Indena S.P.A.
Priority to SI200230247T priority patent/SI1363588T1/en
Priority to AT02703604T priority patent/ATE314050T1/en
Priority to JP2002571010A priority patent/JP4351447B2/en
Priority to PL363649A priority patent/PL204103B1/en
Priority to DE60208342T priority patent/DE60208342T2/en
Priority to IL15763002A priority patent/IL157630A0/en
Publication of WO2002072051A2 publication Critical patent/WO2002072051A2/en
Priority to IL157630A priority patent/IL157630A/en
Publication of WO2002072051A3 publication Critical patent/WO2002072051A3/en
Priority to NO20033847A priority patent/NO333511B1/en
Priority to HK04103980A priority patent/HK1060975A1/en
Priority to US11/802,807 priority patent/US20080175802A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material

Definitions

  • the phospholipid complexes of standardized extract of Vitis vinifera (also referred to as "components b") are disclosed in EP 0.275.224.
  • the phospholipid complexes of triterpenes extracted from Glycyrrhiza glabra are disclosed in EP 0.283.713. They exert powerful anti-inflammatory action upon topical administration, inhibiting the conversion of cortisol from its active to inactive form through inhibition of tissular 11 -beta hydroxysteroidehydrogenese, extending the anti-inflammatory action of cortisol released following an inflammatory stimulus.
  • Components c) proved capable of inhibiting by 95% the edema induced in the experimental animal paw through inoculation of croton oil, showing greater effectiveness than common non-steroidal anti-inflammatories (in this case indomethacin).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations, containing ingredients of vegetable origin, in addition to conventional sun filters and excipients.

Description

"PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR THE PROTECTION OF THE SKIN FROM DAMAGES INDUCED BY SUN RADIATIONS"
The present invention relates to pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations, containing ingredients of vegetable origin, in addition to conventional sun filters and excipients. More particularly, the present invention relates to pharmaceutical and cosmetics compositions for the protection of the skin from damages induced by sun radiations, containing phospholipid complexes of flavanolignanes extracted from Silybum marianum; phospholipid complexes of Vitis vinifera standardized extract and phospholipid complexes of triterpenes extracted from Glycyrrhiza glabra, in addition to conventional sun filters and excipients.
The formulation of preparations containing high-protection, specific sun filters has been one of the leading sectors of dermocosmetic research. This is due to the increasing market demand on the ground of both an ever increasing awareness of the public of the harmful effects of sun radiations and to the problem of the reduction of the ozone levels in the atmosphere.
Research in this field has allowed the formulation of diversified preparations, depending on the needs: products for intense exposure to sunlight (for example at the sea or in the mountains), for daily use (anti- aging) or for special uses, as is the case with exposure to UV rays for occupational reasons or in diseases of the pigmentary system (albinism, vitiligo).
Furthermore, there has recently been growth in the knowledge of the molecular mechanisms responsible for the consequences of the lack of protection from sunlight. This allows the formulation of preparations capable of opposing, at any level, the serious consequences which may be caused by non-protected exposure to sunlight. As it is well known, long exposure to sunlight, as well as to ultraviolet radiations, may cause dermatological disorders, even to a serious degree.
The non-ionizing electromagnetic radiation of the UV spectrum makes up the sun emission portion which is today recognized as the main cause of skin alteration. The UV radiations which reach the earth's surface are UV - A (320 to 400 nm) and the UV-B (290 to 320 nm).
Disorders induced by UV radiations are herein generally referred to as "photodermatosis".
Mediated (toxic or allergic reactions to sunlight) and idiopathic (urticaria Solaris, polymorphic dermatitis, actinic reticuloid) photodermatosis, as well as those liable to be worsened by sunlight (pellagra, lupus erythematosus, pemphigus erythematosus, xeroderma pigmentosum, dermatomyositis) may be considered as somewhat rare consequences of exposure to light. Conversely, direct photodermatosis is by far more frequent. Photodermatosis may appear as erythema/edema vesiculosum reaction
(acute damage), photo-aging and photo-carcinogenesis (chronic damage). Erythema
Erythema is the most frequent skin reaction to UV radiation. It is dose-dependent and may range from modest, asymptomatic skin reddening to serious erythema which may be accompanied by pain, edema and the formation of vesicles. Erythema results from a peripheral capillary vasodilatation and is the consequence of both a direct interaction with blood vessels and a photochemical reaction triggered by sunrays on tissue chromophores (aromatic amino acids, nitrogenous bases, unsaturated fatty acids, etc.). A number of mediators are apparently involved in these interactions: prostaglandins of the E and D series, interleukins and mainly free radicals. The latter are released as a consequence of the energy transferred from chromophores to molecular oxygen, and are responsible for most of the vascular damage caused by exposure to sunlight. Photo-aging
Skin aging is a complex biological process affecting various skin layers, including dermis. The aging process of those skin areas that are exposed to atmospheric agents is due, in addition to the so-called innate or intrinsic aging, namely the irreversible, degenerative process connected with aging which affects both the skin and internal organs, also to the extrinsic or photo-determined aging, which is mainly linked to ultraviolet exposure. According to recent investigations, 80% of total damage in the areas exposed to atmospheric agents is determined by exposure to sunlight. From a cosmetic and pharmaceutical point of view, however, it is clear that action can be taken only against the second type of aging.
The above mentioned genesis of oxygen free radicals in turn promotes oxidative stress which damages such tissutal structures as endothelial membranes, proteins, nucleic acids and connective fibers. The consequences are: excessive microcirculation permeability, which causes tissue hypoxia and edema; - protein denaturization, which is particularly dangerous in the case of structural proteins and enzymes; lipidic peroxidation, which leads to cell death; connective sclerosis. A further damage induced by UV radiation is an increase in the transcription and translation processes of a particular DNA segment encoding for some metalloproteins exerting an effective digestive activity on collagen. This occurs at a speed markedly higher than that of reparative processes that act on the connective matrices, resulting in skin damage and the appearance of wrinkles. Photo-carcinogenesis
Epidemiologic and clinical evidence has now demonstrated how deeply sun radiations, an in particular UV radiation, are involved in the development of some pre-cancerous conditions (actinic keratoses) which may evolve into neoplastic lesions, such as basal cell epithelioma, spinocellular epithelioma and melanoma, which is the most dangerous.
So far, three are the mechanisms apparently involved in the development of neoplasms caused by UV radiation: mutation induced by the direct interaction with nitrogenous bases, interaction between free radicals and DNA, and UV-mediated immunosuppression induced at the skin level on the key cells in the immune response, namely dendritic cells, which are no longer capable of exerting an effective immune response that could suppress tumoral lesion. In conclusion, it is clear that a tool aimed at providing a complete protection of the skin against any UV-mediated damage should be able to filter UV radiation, as well as act against oxidative stress, digestion of the connective tissue mucopolysaccharide fibers, mutagenic activity and UV- mediated immunosuppression. However, the preparations at present marketed do not meet all of the above cited requirements.
The present invention meets the above indicated requirements, providing pharmaceutical and cosmetic compositions which, in addition to conventional sun filters and excipients, also contain at least two of the following ingredients of vegetable origin: a) phospholipid complexes of flavanolignanes 0.1 - 5% extracted from Silybum marianum b) phospholipid complexes of standardized 0.1 - 5% extract of Vitis vinifera c) phospholipid complexes of triterpenes 0.1 - 5% extracted from Glycyrrhiza glabra
The pharmaceutical and cosmetic compositions of the present invention preferably contain at least two of the following ingredients of vegetable origin in the following percentages: a) phospholipid complexes of flavanolignanes 0.5% extracted from Silybum marianum b) phospholipid complexes of standardized 1.5% extract of Vitis vinifera c) phospholipid complexes of triterpenes 1.5% extracted from Glycyrrhiza glabra in combination with conventional sun filters and excipients.
The phospholipid complexes of flavanolignanes extracted from
Silybum marianum (also referred to as "components a") are disclosed in EP 0.209.038.
They are characterized by excellent antioxidizing and antiinflammatory properties. In tests using CCI4 as a pro-oxidant stimulus and hepatic microsomes as the target, the LC50 (micrograms per ml) of components a) corresponds to 25.0, while that of vitamin E (as the reference compound) is 30.0. As far as the antiinflammatory activity is concerned, components a) proved capable of inhibiting by 75% edema induced in the experimental animal paw through inoculation of croton oil. In man, components a), tested in 20 healthy volunteers against placebo, proved capable of inhibiting by 25% the erythematous reaction produced by skin exposure to ultraviolet radiation.
The phospholipid complexes of standardized extract of Vitis vinifera (also referred to as "components b") are disclosed in EP 0.275.224.
In-vitro assays demonstrated the extremely powerful antioxidant activity of components b). In tests using Fe+++/ADP as a stimulus and liposomial preparations as the target of oxidation, components b) proved to be 35 times more active than catechin and 50 times more active than vitamin E. It should also be underlined that these complexes inhibit by 95% lipidic peroxidation induced by ultraviolet radiation, even at concentrations as low as 10 micromoles.
Components b) also proved to be able to inhibit, though in a non- competitive way, any elastase, collagenase and hyaluronidase present in inflamed tissue: this characteristic is extremely useful for a product developed to contrast skin photo-aging. In recent mutagenesis assays, components b) showed excellent anti- mutagenic properties. Tests on spontaneous mutation of Saccharomyces cerevisiae (yeast and eukaryotic cells) demonstrated that these complexes can reverse mutation of the mitochondrial and nuclear DNA by 60% and 90%, respectively (0.5 mg/ml). The anti-immunosuppressive properties of components b) were also evaluated. Components b), applied topically on the skin of nude mice and tested against placebo, inhibit UV-mediated skin immunosuppression by about 50%. In man, test in 18 healthy volunteers showed an 30% inhibition of the erythematous reaction produced by skin exposure to ultraviolet radiation.
The phospholipid complexes of triterpenes extracted from Glycyrrhiza glabra (also referred to as "components c") are disclosed in EP 0.283.713. They exert powerful anti-inflammatory action upon topical administration, inhibiting the conversion of cortisol from its active to inactive form through inhibition of tissular 11 -beta hydroxysteroidehydrogenese, extending the anti-inflammatory action of cortisol released following an inflammatory stimulus. Components c) proved capable of inhibiting by 95% the edema induced in the experimental animal paw through inoculation of croton oil, showing greater effectiveness than common non-steroidal anti-inflammatories (in this case indomethacin).
Components a), b) and c) were also toxicologically tested. The results of the acute toxicity tests carried out in the rat are summarized in the following Table.
Component oral LD50 intraperitoneal LD50 mg/kg mg/kg a) > 3.000 > 2.000 b) > 5.000 > 2.221 c) > 2.000 > 4.432
Furthermore, acute and chronic cutaneous irritation tests in the eye carried out on the rabbit proved that components a), b) and c) do not exert irritative action.
Neither sensitization nor intolerance symptoms were observed in skin tests on healthy volunteers.
The compositions of the present invention will be administered topically, in the form of suitable formulations both liquid (such as gel, lotions, milks, emulsions, foams and the like) and solid or semi-solid (such as creams, ointments, lipsticks, and the like). Said formulations will be prepared according to conventional methods, such as those described in "Remington's Pharmaceutical Handbook", Mack Publishing Co, NY, USA, together with suitable excipients, such as emollients, moisturizers, thickening agents, emulsifiers, dyes, flavours and the like.

Claims

1. Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations, containing at least two of the following ingredients of vegetable origin: a) phospholipid complexes of flavanolignanes 0.1 - 5% extracted from Silybum marianum b) phospholipid complexes of standardized 0.1 - 5% extract of Vitis vinifera c) phospholipid complexes of triterpenes 0.1 - 5% extracted from Glycyrrhiza glabra in combination with conventional sun filters and excipients.
2. Pharmaceutical and cosmetic compositions as claimed in claim 1, containing at least two of the following ingredients of vegetable origin: a) phospholipid complexes of flavanolignanes 0.5% extracted from Silybum marianum b) phospholipid complexes of standardized 1.5% extract of Vitis vinifera c) phospholipid complexes of triterpenes 1.5% extracted from Glycyrrhiza glabra in combination with sun filters and conventional excipients.
3. The use of at least two of the following components: a) phospholipid complexes of flavanolignanes extracted from Silybum marianum; b) phospholipid complexes of Vitis vinifera polyphenolic fraction; c) phospholipid complexes of triterpenes extracted from Glycyrrhiza glabra; for the preparation of pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations.
PCT/EP2002/002027 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations WO2002072051A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IL15763002A IL157630A0 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
AU2002237310A AU2002237310B2 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
HU0303375A HU230038B1 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
US10/469,300 US7374748B2 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
SK1088-2003A SK285876B6 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic composition for protection of skin from damage induced by sun radiation and use thereof
EP02703604A EP1363588B1 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
JP2002571010A JP4351447B2 (en) 2001-03-02 2002-02-26 Medicinal cosmetic composition for protecting skin from injury from sunlight
SI200230247T SI1363588T1 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
AT02703604T ATE314050T1 (en) 2001-03-02 2002-02-26 PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR PROTECTING THE SKIN AGAINST SOLAR RADIATION DAMAGE
CA2439685A CA2439685C (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
PL363649A PL204103B1 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
DE60208342T DE60208342T2 (en) 2001-03-02 2002-02-26 PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR THE PROTECTION OF THE SKIN AGAINST SUNSHAVIOR DAMAGE
KR1020037010928A KR100894581B1 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
IL157630A IL157630A (en) 2001-03-02 2003-08-28 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
NO20033847A NO333511B1 (en) 2001-03-02 2003-08-29 PHARMASOYTIC AND COSMETIC COMPOSITIONS FOR THE PROTECTION OF SKIN AGAINST SUN RAYS
HK04103980A HK1060975A1 (en) 2001-03-02 2004-06-03 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
US11/802,807 US20080175802A1 (en) 2001-03-02 2007-05-25 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2001A000429 2001-03-02
IT2001MI000429A ITMI20010429A1 (en) 2001-03-02 2001-03-02 PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR THE PROTECTION OF THE SKIN DAMAGES INDUCED BY SOLAR RADIATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/802,807 Division US20080175802A1 (en) 2001-03-02 2007-05-25 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations

Publications (2)

Publication Number Publication Date
WO2002072051A2 true WO2002072051A2 (en) 2002-09-19
WO2002072051A3 WO2002072051A3 (en) 2003-08-28

Family

ID=11447085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002027 WO2002072051A2 (en) 2001-03-02 2002-02-26 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations

Country Status (22)

Country Link
US (2) US7374748B2 (en)
EP (1) EP1363588B1 (en)
JP (1) JP4351447B2 (en)
KR (1) KR100894581B1 (en)
CN (1) CN1248677C (en)
AT (1) ATE314050T1 (en)
AU (1) AU2002237310B2 (en)
CA (1) CA2439685C (en)
CZ (1) CZ299436B6 (en)
DE (1) DE60208342T2 (en)
DK (1) DK1363588T3 (en)
ES (1) ES2254647T3 (en)
HK (1) HK1060975A1 (en)
HU (1) HU230038B1 (en)
IL (2) IL157630A0 (en)
IT (1) ITMI20010429A1 (en)
NO (1) NO333511B1 (en)
PL (1) PL204103B1 (en)
RU (1) RU2284191C2 (en)
SI (1) SI1363588T1 (en)
SK (1) SK285876B6 (en)
WO (1) WO2002072051A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043671A1 (en) * 2007-10-04 2009-04-09 Madaus, S.A. Use of a silybum marianum extract

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010429A1 (en) * 2001-03-02 2002-09-02 Indena Spa PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR THE PROTECTION OF THE SKIN DAMAGES INDUCED BY SOLAR RADIATIONS
FR2986154B1 (en) * 2012-01-31 2017-08-04 Pierre Fabre Dermo-Cosmetique NEW PHOTOPROTECTIVE SYSTEM
US8877259B2 (en) 2012-02-09 2014-11-04 Mary Kay Inc. Cosmetic formulation
US9056063B2 (en) 2012-03-13 2015-06-16 James E. Hanson Natural sunscreen composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764508A (en) * 1985-07-17 1988-08-16 Inverni Della Beffa S.P.A. Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions
EP0283713A2 (en) * 1987-02-26 1988-09-28 INDENA S.p.A. Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
US4963527A (en) * 1987-01-14 1990-10-16 Indena S.P.A. Phospholipid complexes of extracts of vitis vinifera, their preparation process and pharmaceutical and cosmetic compositions containing them
EP0552439A1 (en) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Pharmaceutical preparations for topical use in the treatment of psoriasis and atopical dermatitis
WO2000064472A1 (en) * 1999-04-22 2000-11-02 Howard Murad Methods and compositions for treating dermatological disorders with fruit extracts
EP1072254A1 (en) * 1998-04-24 2001-01-31 Sunstar Inc. Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US764508A (en) * 1904-03-25 1904-07-05 Thomas Harrison Symington Dust-guard for journal-boxes.
IT1288257B1 (en) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De COMPOSITION FOR COSMETIC, PHARMACEUTICAL OR DIETETIC USE BASED ON AN AMINO SUGAR AND / OR A POLYHYDROXYL ACID
ITMI20010429A1 (en) * 2001-03-02 2002-09-02 Indena Spa PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR THE PROTECTION OF THE SKIN DAMAGES INDUCED BY SOLAR RADIATIONS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764508A (en) * 1985-07-17 1988-08-16 Inverni Della Beffa S.P.A. Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions
US4963527A (en) * 1987-01-14 1990-10-16 Indena S.P.A. Phospholipid complexes of extracts of vitis vinifera, their preparation process and pharmaceutical and cosmetic compositions containing them
EP0283713A2 (en) * 1987-02-26 1988-09-28 INDENA S.p.A. Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
EP0552439A1 (en) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Pharmaceutical preparations for topical use in the treatment of psoriasis and atopical dermatitis
EP1072254A1 (en) * 1998-04-24 2001-01-31 Sunstar Inc. Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
WO2000064472A1 (en) * 1999-04-22 2000-11-02 Howard Murad Methods and compositions for treating dermatological disorders with fruit extracts

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043671A1 (en) * 2007-10-04 2009-04-09 Madaus, S.A. Use of a silybum marianum extract

Also Published As

Publication number Publication date
WO2002072051A3 (en) 2003-08-28
DE60208342D1 (en) 2006-02-02
RU2003126481A (en) 2005-02-27
PL204103B1 (en) 2009-12-31
ITMI20010429A1 (en) 2002-09-02
EP1363588B1 (en) 2005-12-28
JP4351447B2 (en) 2009-10-28
CZ20032336A3 (en) 2004-07-14
CA2439685C (en) 2010-01-26
AU2002237310B2 (en) 2006-02-02
KR20040025896A (en) 2004-03-26
CN1248677C (en) 2006-04-05
US20040115141A1 (en) 2004-06-17
HUP0303375A2 (en) 2004-01-28
DE60208342T2 (en) 2006-07-13
SK285876B6 (en) 2007-10-04
HU230038B1 (en) 2015-05-28
SK10882003A3 (en) 2004-01-08
IL157630A0 (en) 2004-03-28
HUP0303375A3 (en) 2012-09-28
IL157630A (en) 2007-07-04
HK1060975A1 (en) 2004-09-03
CZ299436B6 (en) 2008-07-23
NO20033847L (en) 2003-10-23
NO20033847D0 (en) 2003-08-29
KR100894581B1 (en) 2009-04-24
DK1363588T3 (en) 2006-05-22
EP1363588A2 (en) 2003-11-26
JP2004519487A (en) 2004-07-02
US7374748B2 (en) 2008-05-20
ES2254647T3 (en) 2006-06-16
ATE314050T1 (en) 2006-01-15
RU2284191C2 (en) 2006-09-27
PL363649A1 (en) 2004-11-29
NO333511B1 (en) 2013-06-24
CN1494414A (en) 2004-05-05
CA2439685A1 (en) 2002-09-19
US20080175802A1 (en) 2008-07-24
SI1363588T1 (en) 2006-04-30

Similar Documents

Publication Publication Date Title
US7892523B2 (en) Cosmetic process for the treatment of the skin with sun-protection products and sun-protection products combination
WO2011112414A2 (en) Compound, composition, and method for protecting skin from high energy visible light
ITRM20000520A1 (en) COSMETIC FORMULATION.
US20080175802A1 (en) Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
JP2003504319A (en) Self-tanning composition containing DHA and propolis extract
AU2007332800A1 (en) Creatine compositions for skin treatment
JP2000504307A (en) Depigmented skin and / or cosmetic composition
AU2002237310A1 (en) Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
JP2002308750A (en) Skin care preparation
KR19990006295A (en) Use of Sulfite and Metabisulfite, in particular in dermatology, for the preparation of cosmetic or pharmaceutical compositions with melanogenesis-inhibiting or decolorizing activity
JP3432033B2 (en) Photoaging agent and skin cosmetic containing the same
JP3119622B2 (en) Cosmetics
JPH01139517A (en) Cosmetic
KR102031663B1 (en) Cosmetic composition and external composition comprising glucosyl withanolides for anti-inflammatory
EP1338269A1 (en) Composition for whitening the skin and alleviating of pigmentation disorders containing creatinine and/or a creatinine derivative as active ingredient
KR102031662B1 (en) Cosmetic composition and external composition comprising steroidal lactones for anti-inflammatory
JP2006052165A (en) Skin composition for external use
WO1998025585A1 (en) Skin protecting agent
JPH04244005A (en) Cosmetic
JPH08127521A (en) Ultraviolet absorbing agent
Jondhale et al. Potential of Herbs in Skin-Care

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1020037010928

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 01345/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 157630

Country of ref document: IL

Ref document number: 10882003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2003-2336

Country of ref document: CZ

Ref document number: 2002703604

Country of ref document: EP

Ref document number: 2002571010

Country of ref document: JP

Ref document number: 2002237310

Country of ref document: AU

Ref document number: 028057481

Country of ref document: CN

Ref document number: 2439685

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002703604

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10469300

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037010928

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-2336

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002703604

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002237310

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: PV2003-2336

Country of ref document: CZ